SCHEDULE: Citadel Reports 5.1% Stake in Cullinan Therapeutics

Kenneth Griffin and Citadel entities report a combined beneficial ownership of 5.1% in Cullinan Therapeutics, Inc. common stock.

Summary

• Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin have jointly filed a Schedule 13G.
• The filing reports beneficial ownership of Cullinan Therapeutics, Inc. common stock, par value $0.0001 per share.
• Kenneth Griffin beneficially owns 3,009,126 shares, representing 5.1% of the outstanding shares.
• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 2,511,191 shares, representing 4.3% of the outstanding shares.
• Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 497,935 shares, representing 0.8% of the outstanding shares.
• All reported shares have shared voting and shared dispositive power, with no sole voting or dispositive power held by any reporting person.
• The percentages are based on 59,014,667 shares outstanding as of April 30, 2025, as reported in the issuer's Form 10-Q filed on May 8, 2025.
• The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a prominent institutional investor like Citadel and its founder, Kenneth Griffin, is generally viewed positively as it indicates institutional interest and potential confidence in the company, even without explicit performance data.

Positives

• A significant institutional investor, Citadel and its affiliates, along with Kenneth Griffin, have disclosed a substantial passive stake in Cullinan Therapeutics, which may signal confidence in the company's long-term prospects.

Negatives

• The filing, being a beneficial ownership report, does not contain negative information regarding Cullinan Therapeutics' operational performance or financial health.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing the control of the issuer, mitigating risks associated with activist investor intentions.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by a major investment firm and does not provide specific industry context or trends beyond the fact of institutional investment in the biotechnology/pharmaceutical sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional shareholder may increase investor confidence and potentially attract further institutional interest in the stock.

Next Steps

• NA

Key Dates

Recommendation

The Schedule 13G filing indicates a significant passive investment by Citadel and Kenneth Griffin in Cullinan Therapeutics. While this signals institutional interest and potential confidence, the filing itself does not provide financial performance data or strategic updates to warrant a stronger buy or sell recommendation. It is a disclosure of ownership, not an operational report, thus a 'hold' recommendation is appropriate given the limited information for a fundamental re-evaluation.

Keywords

Cullinan Therapeutics, Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Investment